TW200801043A - Human monoclonal antibodies to activin receptor-like kinase-1 - Google Patents
Human monoclonal antibodies to activin receptor-like kinase-1Info
- Publication number
- TW200801043A TW200801043A TW095132933A TW95132933A TW200801043A TW 200801043 A TW200801043 A TW 200801043A TW 095132933 A TW095132933 A TW 095132933A TW 95132933 A TW95132933 A TW 95132933A TW 200801043 A TW200801043 A TW 200801043A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibodies
- alk
- relates
- kinase
- activin receptor
- Prior art date
Links
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 title abstract 4
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 abstract 1
- 101700032040 SMAD1 Proteins 0.000 abstract 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71529205P | 2005-09-07 | 2005-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200801043A true TW200801043A (en) | 2008-01-01 |
TWI370137B TWI370137B (en) | 2012-08-11 |
Family
ID=37906640
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103138817A TWI569807B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
TW095132933A TWI370137B (en) | 2005-09-07 | 2006-09-06 | Human monoclonal antibodies to activin receptor-like kinase-1 |
TW103116433A TWI541253B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
TW101141374A TWI453218B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
TW099108743A TWI389919B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103138817A TWI569807B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103116433A TWI541253B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
TW101141374A TWI453218B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
TW099108743A TWI389919B (zh) | 2005-09-07 | 2006-09-06 | 針對類活化素受體激酶-1之人類單株抗體 |
Country Status (41)
Country | Link |
---|---|
US (3) | US7537762B2 (zh) |
EP (4) | EP2447283B1 (zh) |
JP (3) | JP5161777B2 (zh) |
KR (3) | KR101390127B1 (zh) |
CN (2) | CN107056943B (zh) |
AP (2) | AP2013006963A0 (zh) |
AR (2) | AR055152A1 (zh) |
AU (1) | AU2006297571B2 (zh) |
BR (1) | BRPI0615766A2 (zh) |
CA (1) | CA2621371C (zh) |
CL (1) | CL2010000096A1 (zh) |
CR (3) | CR9819A (zh) |
CY (1) | CY1120794T1 (zh) |
DK (3) | DK2447283T3 (zh) |
DO (1) | DOP2006000195A (zh) |
EA (2) | EA201300320A1 (zh) |
ES (3) | ES2681656T3 (zh) |
GE (1) | GEP20125398B (zh) |
GT (1) | GT200600406A (zh) |
HK (2) | HK1169999A1 (zh) |
HN (1) | HN2006031275A (zh) |
HU (2) | HUE038941T2 (zh) |
IL (2) | IL189642A (zh) |
LT (1) | LT2960253T (zh) |
MA (1) | MA29843B1 (zh) |
ME (1) | ME00501B (zh) |
MY (1) | MY164457A (zh) |
NL (1) | NL1032452C2 (zh) |
NO (1) | NO20081718L (zh) |
NZ (1) | NZ566774A (zh) |
PE (1) | PE20080035A1 (zh) |
PL (3) | PL2447283T3 (zh) |
PT (3) | PT1933871E (zh) |
RS (1) | RS54393B1 (zh) |
SI (3) | SI2960253T1 (zh) |
TN (1) | TNSN08080A1 (zh) |
TW (5) | TWI569807B (zh) |
UA (1) | UA94060C2 (zh) |
UY (1) | UY29783A1 (zh) |
WO (1) | WO2007040912A2 (zh) |
ZA (1) | ZA200802971B (zh) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US7897581B2 (en) * | 2005-02-24 | 2011-03-01 | Massachusetts Eye & Ear Infirmary | Methods and compounds for promoting vessel regression |
JP5161777B2 (ja) * | 2005-09-07 | 2013-03-13 | アムジェン フレモント インク. | アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体 |
CA2623729A1 (en) * | 2006-02-10 | 2007-08-16 | Nerviano Medical Sciences S.R.L. | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
AU2012265564B2 (en) * | 2006-09-08 | 2016-05-26 | Amgen Inc | Anti-activin A antibodies and uses thereof |
AU2016247166B2 (en) * | 2006-11-02 | 2018-09-27 | Acceleron Pharma Inc. | ALK1 receptor and ligand antagonists and uses thereof |
CN101652387A (zh) * | 2006-11-02 | 2010-02-17 | 阿塞勒隆制药公司 | Alk1受体和配体拮抗剂及其用途 |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
AU2008236765A1 (en) * | 2007-04-02 | 2008-10-16 | Amgen Fremont Inc. | Anti-IgE antibodies |
ITTV20070126A1 (it) | 2007-07-16 | 2009-01-17 | Luca Toncelli | Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato |
TW200924796A (en) * | 2007-11-09 | 2009-06-16 | Genentech Inc | Activin receptor-like kinase-1 compositions and methods of use |
AU2008323206B2 (en) * | 2007-11-12 | 2014-08-14 | U3 Pharma Gmbh | AXL antibodies |
CA2712000A1 (en) * | 2008-01-28 | 2009-08-06 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
US7855564B2 (en) * | 2008-02-14 | 2010-12-21 | Delaware Capital Formation, Inc. | Acoustic wave device physical parameter sensor |
US20110110944A1 (en) * | 2008-04-25 | 2011-05-12 | Morphosys Ag | Anti-alk1 antibodies and uses thereof |
CN102099374B (zh) * | 2008-05-02 | 2016-06-08 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
EP2291401A2 (en) * | 2008-05-15 | 2011-03-09 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
CN104371024A (zh) | 2008-11-26 | 2015-02-25 | 安姆根有限公司 | 激活素iib受体多肽的变异体及其用途 |
WO2010126169A1 (ja) * | 2009-04-30 | 2010-11-04 | 協和発酵キリン株式会社 | Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物 |
GB0915515D0 (en) * | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
AU2011268934B2 (en) * | 2010-06-25 | 2015-09-10 | Nykode Therapeutics ASA | Homodimeric protein constructs |
MX358358B (es) | 2011-12-19 | 2018-08-15 | Amgen Inc | Polipeptidos de receptores de activina variantes y sus usos. |
JP6413127B2 (ja) | 2012-01-09 | 2018-10-31 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 変異抗体およびそのコンジュゲーション |
WO2013155447A1 (en) | 2012-04-13 | 2013-10-17 | Children's Medical Center Corporation | Tiki inhibitors |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
MX2015009901A (es) * | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administración de un compuesto de antiactivina a a un sujeto. |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
EP2787006B1 (en) * | 2013-04-02 | 2018-02-28 | Miltenyi Biotec GmbH | Anti-CD8 antibody which binding is Ca2+ dependent |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
WO2016054023A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
GB201503438D0 (en) | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
KR101983013B1 (ko) * | 2015-09-25 | 2019-05-28 | 동우 화인켐 주식회사 | 필름 터치 센서 및 그 제조 방법 |
JP2017077830A (ja) * | 2015-10-21 | 2017-04-27 | Kyb株式会社 | 電動パワーステアリング装置 |
US11236156B2 (en) | 2016-02-11 | 2022-02-01 | The Johns Hopkins University | Compositions and methods for targeting activin signaling to treat cancer |
RU2615908C1 (ru) * | 2016-05-16 | 2017-04-11 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс |
WO2018027124A1 (en) * | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anti-o2 antibodies and uses thereof |
CA3039686A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
SG11202009216YA (en) | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
CN115925900A (zh) * | 2020-08-19 | 2023-04-07 | 重庆医科大学 | 新型冠状病毒rbd特异性单克隆抗体和应用 |
JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
CN115746142A (zh) * | 2021-09-03 | 2023-03-07 | 开拓药业(广东)有限公司 | 抗alk-1/抗vegf双特异性抗体及其应用 |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
JPH0341802A (ja) | 1989-07-07 | 1991-02-22 | Ngk Spark Plug Co Ltd | 温度補償型マイクロ波ストリップラインフィルタ |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) * | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US7592428B1 (en) * | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
NZ257631A (en) | 1992-11-17 | 1996-03-26 | Ludwig Inst Cancer Res | Serine/threonine kinase domain-containing protein, dna and hosts therefor |
US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
KR100479146B1 (ko) | 1995-04-21 | 2005-05-16 | 셀 제네시스, 인코포레이티드 | 큰게놈dna결실유발법 |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CA2229557A1 (en) * | 1995-08-14 | 1997-02-27 | Creative Biomolecules, Inc. | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5663272A (en) * | 1995-12-22 | 1997-09-02 | Bayer Corporation | Allophanate-modified diphenylmethane diisocyanates and processes for their production and use |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US6180651B1 (en) | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
DE19616523A1 (de) * | 1996-04-25 | 1997-11-06 | Basf Ag | Polymerisationskatalysatoren mit beta-Diketiminat-Liganden |
EP0907649A1 (en) * | 1996-06-27 | 1999-04-14 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
AU3766897A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DK0912518T3 (da) | 1996-07-18 | 2003-12-08 | Merck Frosst Canada Inc | Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
WO2002024719A1 (en) | 2000-09-20 | 2002-03-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE292623T1 (de) | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
KR100446363B1 (ko) | 1997-11-11 | 2004-09-01 | 화이자 프로덕츠 인코포레이티드 | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
JPH11236333A (ja) * | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
EP2078752A3 (en) * | 1998-03-13 | 2009-09-23 | Ludwig Institute For Cancer Research | ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
EP1082305A4 (en) | 1998-05-29 | 2001-09-26 | Sugen Inc | PYRROL SUBSTITUTED 2-INDOLINONE EFFECTIVE AS A PROTEIN KINASE INHIBITOR |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
ES2237125T3 (es) * | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
CA2341690C (en) * | 1998-08-27 | 2007-04-17 | Pfizer Products Inc. | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EP2112166B1 (en) | 1998-12-23 | 2018-11-21 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
CZ20012910A3 (cs) * | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroarylem-substituované chinolin-2-onové deriváty pouľitelné jako protinádorové prostředky |
US5998206A (en) * | 1999-02-23 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense inhibiton of human G-alpha-12 expression |
US6586447B1 (en) * | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
KR100478111B1 (ko) | 1999-11-05 | 2005-03-28 | 가부시키가이샤 아마다 | 프레스 브레이크 및 프레스 브레이크에 있어서의 유압실린더의 쌍방향 유체 펌프 제어 방법 |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
ES2212971T3 (es) * | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
CN1250288C (zh) * | 1999-12-15 | 2006-04-12 | 研究发展基金会 | 作为抑制素受体的β聚糖及其用途 |
EA005996B1 (ru) | 2000-02-15 | 2005-08-25 | Сьюджен, Инк. | Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой |
US6584504B1 (en) * | 2000-05-26 | 2003-06-24 | Networks Associates Technology, Inc. | Method and apparatus for monitoring internet traffic on an internet web page |
AP2001002192A0 (en) | 2000-06-22 | 2002-12-21 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth. |
CN1854157B (zh) | 2001-01-05 | 2013-01-02 | 辉瑞大药厂 | 胰岛素样生长因子i受体的抗体 |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
EP2009027B1 (en) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
JP2005538682A (ja) * | 2001-12-03 | 2005-12-22 | アブジェニックス・インコーポレーテッド | カルボキシックアンヒドラーゼix(caix)腫瘍抗原に対する抗体 |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
EP1467756A4 (en) * | 2001-12-28 | 2007-03-21 | Abgenix Inc | METHODS OF USING ANTI-MUC18 ANTIBODIES |
PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
JP4754219B2 (ja) * | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
CN103087941B (zh) | 2005-02-04 | 2015-09-16 | Cp凯尔科美国公司 | 多糖粘液形成菌的靶基因缺失 |
JP5161777B2 (ja) * | 2005-09-07 | 2013-03-13 | アムジェン フレモント インク. | アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体 |
JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2006
- 2006-09-06 JP JP2008530231A patent/JP5161777B2/ja active Active
- 2006-09-06 CN CN201611215981.7A patent/CN107056943B/zh active Active
- 2006-09-06 HN HN2006031275A patent/HN2006031275A/es unknown
- 2006-09-06 EP EP12152953.1A patent/EP2447283B1/en active Active
- 2006-09-06 WO PCT/US2006/035096 patent/WO2007040912A2/en active Application Filing
- 2006-09-06 PE PE2006001075A patent/PE20080035A1/es not_active Application Discontinuation
- 2006-09-06 EA EA201300320A patent/EA201300320A1/ru unknown
- 2006-09-06 SI SI200632285T patent/SI2960253T1/sl unknown
- 2006-09-06 AP AP2013006963A patent/AP2013006963A0/xx unknown
- 2006-09-06 SI SI200631626T patent/SI1933871T1/sl unknown
- 2006-09-06 NL NL1032452A patent/NL1032452C2/nl not_active IP Right Cessation
- 2006-09-06 PL PL12152953T patent/PL2447283T3/pl unknown
- 2006-09-06 AP AP2008004388A patent/AP2723A/xx active
- 2006-09-06 TW TW103138817A patent/TWI569807B/zh active
- 2006-09-06 CA CA2621371A patent/CA2621371C/en active Active
- 2006-09-06 ES ES15169743.0T patent/ES2681656T3/es active Active
- 2006-09-06 UA UAA200804286A patent/UA94060C2/ru unknown
- 2006-09-06 GT GT200600406A patent/GT200600406A/es unknown
- 2006-09-06 KR KR1020087006587A patent/KR101390127B1/ko active IP Right Grant
- 2006-09-06 PT PT68249150T patent/PT1933871E/pt unknown
- 2006-09-06 BR BRPI0615766-1A patent/BRPI0615766A2/pt not_active IP Right Cessation
- 2006-09-06 DK DK12152953.1T patent/DK2447283T3/en active
- 2006-09-06 UY UY29783A patent/UY29783A1/es not_active Application Discontinuation
- 2006-09-06 EP EP15169743.0A patent/EP2960253B1/en active Active
- 2006-09-06 ES ES12152953.1T patent/ES2546069T3/es active Active
- 2006-09-06 DK DK15169743.0T patent/DK2960253T3/en active
- 2006-09-06 PT PT121529531T patent/PT2447283E/pt unknown
- 2006-09-06 EP EP18170945.2A patent/EP3381945B1/en active Active
- 2006-09-06 KR KR1020137007712A patent/KR101536487B1/ko active IP Right Grant
- 2006-09-06 US US11/517,530 patent/US7537762B2/en active Active
- 2006-09-06 TW TW095132933A patent/TWI370137B/zh not_active IP Right Cessation
- 2006-09-06 DK DK06824915.0T patent/DK1933871T3/da active
- 2006-09-06 MY MYPI20080556A patent/MY164457A/en unknown
- 2006-09-06 LT LTEP15169743.0T patent/LT2960253T/lt unknown
- 2006-09-06 TW TW103116433A patent/TWI541253B/zh not_active IP Right Cessation
- 2006-09-06 SI SI200631985T patent/SI2447283T1/sl unknown
- 2006-09-06 EA EA200800759A patent/EA018453B1/ru not_active IP Right Cessation
- 2006-09-06 ES ES06824915T patent/ES2421146T3/es active Active
- 2006-09-06 PL PL15169743T patent/PL2960253T3/pl unknown
- 2006-09-06 AU AU2006297571A patent/AU2006297571B2/en not_active Ceased
- 2006-09-06 NZ NZ566774A patent/NZ566774A/en unknown
- 2006-09-06 DO DO2006000195A patent/DOP2006000195A/es unknown
- 2006-09-06 KR KR1020137033726A patent/KR101536506B1/ko active IP Right Grant
- 2006-09-06 GE GEAP200610627A patent/GEP20125398B/en unknown
- 2006-09-06 PL PL06824915T patent/PL1933871T3/pl unknown
- 2006-09-06 ME MEP-2008-812A patent/ME00501B/me unknown
- 2006-09-06 CN CN200680041490.3A patent/CN101517068B/zh active Active
- 2006-09-06 ZA ZA200802971A patent/ZA200802971B/xx unknown
- 2006-09-06 HU HUE15169743A patent/HUE038941T2/hu unknown
- 2006-09-06 AR ARP060103884A patent/AR055152A1/es not_active Application Discontinuation
- 2006-09-06 TW TW101141374A patent/TWI453218B/zh active
- 2006-09-06 HU HUE12152953A patent/HUE025608T2/en unknown
- 2006-09-06 TW TW099108743A patent/TWI389919B/zh active
- 2006-09-06 RS RS20080103A patent/RS54393B1/en unknown
- 2006-09-06 EP EP06824915.0A patent/EP1933871B1/en active Active
- 2006-09-06 PT PT151697430T patent/PT2960253T/pt unknown
-
2008
- 2008-02-21 TN TNP2008000080A patent/TNSN08080A1/en unknown
- 2008-02-21 IL IL189642A patent/IL189642A/en not_active IP Right Cessation
- 2008-03-14 CR CR9819A patent/CR9819A/es unknown
- 2008-04-01 MA MA30800A patent/MA29843B1/fr unknown
- 2008-04-07 NO NO20081718A patent/NO20081718L/no not_active Application Discontinuation
-
2009
- 2009-03-12 US US12/402,854 patent/US8080646B2/en active Active
-
2010
- 2010-02-04 CL CL2010000096A patent/CL2010000096A1/es unknown
-
2011
- 2011-10-26 US US13/282,065 patent/US9221915B2/en active Active
-
2012
- 2012-03-01 IL IL218429A patent/IL218429A0/en unknown
- 2012-07-02 JP JP2012148146A patent/JP5833978B2/ja active Active
- 2012-10-26 HK HK12110733.7A patent/HK1169999A1/zh not_active IP Right Cessation
-
2013
- 2013-07-19 CR CR20130351A patent/CR20130351A/es unknown
-
2014
- 2014-05-22 CR CR20140239A patent/CR20140239A/es unknown
- 2014-08-13 JP JP2014164638A patent/JP5947840B2/ja active Active
-
2016
- 2016-06-27 HK HK16107449.4A patent/HK1219488A1/zh not_active IP Right Cessation
- 2016-12-20 AR ARP160103944A patent/AR107003A2/es unknown
-
2018
- 2018-08-09 CY CY181100829T patent/CY1120794T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200801043A (en) | Human monoclonal antibodies to activin receptor-like kinase-1 | |
PH12014501872A1 (en) | P-cadherin antibodies | |
MX2019015195A (es) | Anticuerpos contra madcam. | |
TNSN07394A1 (en) | Antibodies to myostatin | |
MX2009006891A (es) | Anticuerpos cd44. | |
AP1918A (en) | Antibodies to CD40 | |
TNSN06080A1 (en) | Antibodies to m-csf | |
EP2511301A3 (en) | Human antibodies to ERBB2 | |
NZ591471A (en) | Antibodies to ccr2 | |
TH117319B (th) | โมโนโคลนอลแอนติบอดีของมนุษย์ต่อไคเนส-1 ที่เหมือนกับแอกทิวินรีเซพเตอร์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |